$1.97
1.01% yesterday
Nasdaq, Oct 31, 09:00 pm CET
ISIN
US45781K2042
Symbol
IPHA

Innate Pharma - ADR Stock price

$1.97
+0.04 2.07% 1M
-0.26 11.66% 6M
+0.13 7.07% YTD
+0.08 4.18% 1Y
-0.18 8.37% 3Y
-2.16 52.32% 5Y
-4.08 67.44% 10Y
-4.08 67.44% 20Y
Nasdaq, Closing price Fri, Oct 31 2025
-0.02 1.01%
ISIN
US45781K2042
Symbol
IPHA
Industry

Key metrics

Basic
Market capitalization
$181.7m
Enterprise Value
$191.4m
Net debt
$9.6m
Cash
$69.6m
Shares outstanding
92.2m
Valuation (TTM | estimate)
P/E
negative | 4.1
P/S
26.1 | 5.2
EV/Sales
27.5 | 5.4
EV/FCF
negative
P/B
30.4
Financial Health
Equity Ratio
8.0%
Return on Equity
-560.0%
ROCE
-79.8%
ROIC
-264.0%
Debt/Equity
13.3
Financials (TTM | estimate)
Revenue
$7.0m | $35.2m
EBITDA
$-57.0m | $74.4m
EBIT
$-58.8m | $24.5m
Net Income
$-53.4m | $44.5m
Free Cash Flow
$-47.9m
Growth (TTM | estimate)
Revenue
-75.9% | 140.5%
EBITDA
-36.6% | 229.4%
EBIT
-31.4% | 141.0%
Net Income
-35.2% | 177.6%
Free Cash Flow
-102.5%
Margin (TTM | estimate)
Gross
49.5%
EBITDA
-819.0% | 211.3%
EBIT
-844.8%
Net
-767.5% | 126.5%
Free Cash Flow
-687.8%
More
EPS
$-0.6
FCF per Share
$-0.5
Short interest
0.1%
Employees
181
Rev per Employee
$80.0k
Show more

Is Innate Pharma - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.

Innate Pharma - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Innate Pharma - ADR forecast:

4x Buy
57%
3x Hold
43%

Analyst Opinions

7 Analysts have issued a Innate Pharma - ADR forecast:

Buy
57%
Hold
43%

Financial data from Innate Pharma - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
6.96 6.96
76% 76%
100%
- Direct Costs 3.51 3.51
1% 1%
50%
3.45 3.45
86% 86%
50%
- Selling and Administrative Expenses 22 22
9% 9%
310%
- Research and Development Expense 44 44
20% 20%
629%
-57 -57
37% 37%
-819%
- Depreciation and Amortization 1.80 1.80
40% 40%
26%
EBIT (Operating Income) EBIT -59 -59
31% 31%
-845%
Net Profit -53 -53
35% 35%
-767%

In millions USD.

Don't miss a Thing! We will send you all news about Innate Pharma - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Innate Pharma - ADR Stock News

Neutral
Seeking Alpha
4 days ago
Innate Pharma S.A. (NASDAQ:IPHA ) Analyst/Investor Day October 28, 2025 8:00 AM EDT Company Participants Jonathan Dickinson - CEO & Director Sonia Quaratino - Executive VP & Chief Medical Officer Stéphanie Cornen Stephanie Cornen - Vice President of Investor Relations, Communication & Commercial Strategy Yannis Morel - Executive VP & COO Conference Call Participants Pierluigi Porcu Chris Stuess...
Neutral
Business Wire
19 days ago
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host an analyst and investor event focused on lacutamab, an asset with path to potential Accelerated Approval based on existing long-term follow-up data of the Phase 2 TELLOMAK study, providing both clinical perspecti...
Neutral
Seeking Alpha
about 2 months ago
Innate Pharma S.A. (NASDAQ:IPHA ) Q2 2025 Earnings Call September 17, 2025 8:00 AM EDT Company Participants Stéphanie Cornen Jonathan Dickinson - CEO & Director Yannis Morel - Executive VP & COO Sonia Quaratino - Executive VP & Chief Medical Officer Frederic Lombard - Senior VP & CFO Conference Call Participants Bill Ling - Leerink Partners LLC, Research Division Swayampakula Ramakanth - H.C.
More Innate Pharma - ADR News

Company Profile

Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells. The company was founded by Hervé Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié and François Romagné on September 15, 1999 and is headquartered in Marseille, France.

Head office France
CEO Jonathan Dickinson
Employees 181
Founded 1999
Website www.innate-pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today